The future of G protein-coupled receptor therapeutics: Apelin receptor acts as a prototype for the advancement of precision drug design

Wei-Wei Wang , Su-Yu Ji , Ping Xu , Yan Zhang , Yan Zhang

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (12) : e70120

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (12) : e70120 DOI: 10.1002/ctm2.70120
COMMENTARY

The future of G protein-coupled receptor therapeutics: Apelin receptor acts as a prototype for the advancement of precision drug design

Author information +
History +
PDF

Cite this article

Download citation ▾
Wei-Wei Wang, Su-Yu Ji, Ping Xu, Yan Zhang, Yan Zhang. The future of G protein-coupled receptor therapeutics: Apelin receptor acts as a prototype for the advancement of precision drug design. Clinical and Translational Medicine, 2024, 14(12): e70120 DOI:10.1002/ctm2.70120

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Chapman NA, Dupré DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol. 2014; 92: 431-440.

[2]

Rozwadowski J, Borodzicz-Jażdżyk S, Czarzasta K, Cudnoch-Jędrzejewska A. A review of the roles of apelin and ELABELA peptide ligands in cardiovascular disease, including heart failure and hypertension. Med Sci Monit. 2022; 28: e938112.

[3]

Yu XH, Tang ZB, Liu LJ, et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta. 2014; 428: 1-8.

[4]

Japp AG, Newby DE. Unlocking the therapeutic potential of apelin. Hypertension. 2016; 68: 307-309.

[5]

Yang P, Read C, Kuc RE, et al. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019; 176: 1206-1221.

[6]

Read C, Nyimanu D, Yang P, et al. The G protein biased small molecule apelin agonist CMF-019 is disease modifying in endothelial cell apoptosis in vitro and induces vasodilatation without desensitisation in vivo. Front Pharmacol. 2020; 11: 588669.

[7]

Brame AL, Maguire JJ, Yang P, et al. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015; 65: 834-840.

[8]

Read C, Fitzpatrick CM, Yang P, et al. Cardiac action of the first G protein biased small molecule apelin agonist. Biochem Pharmacol. 2016; 116: 63-72.

[9]

Wang WW, Ji SY, Zhang W, et al. Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024; 187: 1460-1475.

[10]

Yue Y, Liu L, Wu L-J, et al. Structural insight into apelin receptor-G protein stoichiometry. Nat Struct Mol Biol. 2022; 29: 688-697.

[11]

Ma Y, Ding Y, Song X, et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Sci Adv. 2020; 6: eaax7379.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

180

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/